Researchers say BRCA1 and BRCA2 are very rare among the general population.
研究人员宣称BRCA1和BRCA2在普通人群中罕见。
Therefore, the detection of BRCA1 and BRCA2 gene mutation will be valuable for the prognosis of breast cancer.
通过检测乳腺癌患者BRCA1和BRCA2基因的突变情况，将有助于对乳腺癌患者预后的早期评估。
This gene is different from the breast-cancer susceptibility genes, BRCA1 and BRCA2, which women are born with.
这些基因不同于以往的乳腺癌易感基因BRCA1和BRCA2。以往的易感基因是先天具有的。
Women known to carry a BRCA1 or BRCA2 mutation were identified from an international registry between 1992 and 2003.
该研究通过一个1992-2003年间的国际注册确认那些有BRCA1或BRCA2基因突变的妇女。
The cost of testing for BRCA1 and BRCA2, at more than $3,000 in the United States, remains an obstacle for many women.
测试BRCA1和BRCA2的费用——在美国的的费用要3000多美元（约1.8万元）——将许多女性排斥在外。
Objective To investigate the expression of mutant BRCA2 gene in human breast cancer tissue and its clinic-healing significance.
目的研究突变型BRCA2在人类乳腺癌组织中的表达及其临床康复意义。
But it's far smaller than the fivefold increased risk that comes from inheriting certain mutations in the BRCA1 and BRCA2 genes.
但是，与因继承了乳腺癌易感基因1和乳腺癌易感基因2中的某些基因突变而增加了5倍风险相比，这种冒险是小得多的。
Heredity accounts for about 10% of all breast cancers, and abnormal BRCA1 and BRCA2 genes explain a large number of these cancers.
大约10%的乳腺癌是这一类型，不正常的BRCA1和BRCA2基因是导致这一类型癌症的主要原因。
Of these, 19 patients with a total of 21 tumors had the BRCA1 mutation and eight patients with eight tumors had the BRCA2 mutation.
在这些病患当中，有19病患共有21个肿瘤具有BRCA1突变，八位病患共八个肿瘤具有BRCA2 突变。
Patients with the BRCA2 gene probably have the same prognosis as those without the genes if the tumors have similar characteristics.
在肿瘤特征接近的情况下，BRCA2基因病人与无此基因病人的预后大致相同。
In their normal form, BRCA1 and BRCA2 genes prevent breast cancer by producing a protein that stops cells from growing out of control.
在正常形式下，BRCA1和BRCA2基因通过产生阻止细胞生长失控的蛋白质来预防乳癌。
Identifying BRCA1 and BRCA2 has led to new techniques for lowering, detecting, and treating breast cancer, and lowering the risk for the disease.
BRCA1和BRCA2基因的发现，为乳腺癌的预防、诊断和治疗带来新的技术方法，还降低了乳腺癌治疗的风险。
Purpose to estimate the risk for contralateral breast cancer in members of BRCA1 - and BRCA2-positive families and to determine predictive risk factors.
目的在BRCA1和BRCA2基因表达阳性的家族成员中评估对侧乳腺癌的发病风险，以明确预测风险因子。
On average, around 60 percent of women with a family history of the disease who also carry either a faulty BRCA1 or BRCA2 gene will develop breast cancer.
平均大约60%的伴疾病家族史的、携带有缺陷的BRCA1基因或BRCA2基因的女性将患乳腺癌。
The authors admit that genetic research is progressing, and they cite the example of the discovery of the BRCA1 and BRCA2 genes and their role in breast cancer.
作者承认遗传学研究真正进步，并列举了BRCA1和BRCA2基因发现的例子，以及它们在乳癌中的作用。
The study tracked 1,492 Canadian women with an average age of 48 who did not have mutations in either of two breast cancer susceptibility genes - BRCA1 and BRCA2.
研究人员对1492名平均年龄为48岁的加拿大女性进行了跟踪调查。 她们携带的BRCA1和BRCA2两种乳腺癌易感基因都没有发生突变。
Objective: To investigate the loss of heterozygosity (LOH) of ATM gene and BRCA2 gene and explore the relationship between two genes in patients with ALL and ANLL.
目的：探讨急性淋巴细胞白血病(all)与急性非淋巴细胞白血病(ANLL)AT M基因和BRCA2基因杂合性缺失及其相互关系。
Because current ovarian cancer screening is limited, women with abnormal BRCA1 or BRCA2 genes may decide to have their ovaries removed once child-bearing is completed.
因为最新的卵巢癌筛选受限，有异常的BRCA1或BRCA2基因的女人一旦分娩结束，就决定切除卵巢。
Ever since the discovery that mutations in BRCA1 and BRCA2 genes heighten the risk of breast cancer, scientists have evinced a keen interest in breast cancer genetics.
自从发现基因BRCA1和BRCA2的突变能提高乳腺癌的发生几率后，科学家们就对乳腺癌的相关基因产生了很大的兴趣。
Mutations in the BRCA1 and BRCA2 genes are known to lead to breast and ovarian cancer. However, the frequency of these mutations in the general population has not been well-characterized.
熟知brca1和BRCA2基因突变可引起乳癌和卵巢癌，不过在普通人群中突变的频率还没有很好地描述。
If the process also applies to people, genes such as BRCA1 and BRCA2, which are linked with breast cancer, may not be the only reason why a family history of breast cancer puts a woman at risk.
如果这一过程同样适用于人类的话，则与乳腺癌相关的诸如brca1和BRCA2等基因可能不是乳腺癌家族史内使妇女处于罹患乳腺癌危险之中的唯一原因。
United States District Court Judge Robert W. Sweet issued the 152-page decision, which invalidated seven patents related to the genes BRCA1 and BRCA2, whose mutations have been associated with cancer.
美国联邦地方法院法官Robertw .Sweet宣读了这份长达152页的判决书，该判决书使与BRCA1和BRCA2相关的七种基因专利无效，而BRCA1和BRCA2这两种基因于癌症有关系。
United States District Court Judge Robert W. Sweet issued the 152-page decision, which invalidated seven patents related to the genes BRCA1 and BRCA2, whose mutations have been associated with cancer.
美国联邦地方法院法官Robertw .Sweet宣读了这份长达152页的判决书，该判决书使与BRCA1和BRCA2相关的七种基因专利无效，而BRCA1和BRCA2这两种基因于癌症有关系。
应用推荐